+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Neutralizing Antibody Global Market Report 2025

  • PDF Icon

    Report

  • 175 Pages
  • July 2025
  • Region: Global
  • The Business Research Company
  • ID: 6104970
The neutralizing antibody market size has grown rapidly in recent years. It will grow from $230.25 billion in 2024 to $257.81 billion in 2025 at a compound annual growth rate (CAGR) of 12%. Historical growth has been driven by a rise in biologic drug approvals, increased funding for antibody research, higher prevalence of chronic viral infections, growing awareness of immunotherapy, and expanding healthcare spending.

The neutralizing antibody market size is expected to see rapid growth in the next few years. It will grow to $401.16 billion in 2029 at a compound annual growth rate (CAGR) of 11.7%. This expected growth will be fueled by a rise in emerging infectious diseases, increasing autoimmune disorders, expansion of antibody-based therapy pipelines, growing demand for precision medicine, and increased interest in targeted therapies. Key trends over the forecast period include a shift toward bispecific and multispecific antibodies, the use of artificial intelligence (AI) in antibody discovery, the development of antibody-drug conjugates, increased use of plant-based antibody production, and a rise in personalized immunotherapy approaches.

The increasing prevalence of infectious diseases is anticipated to drive the growth of the neutralizing antibody market in the coming years. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that can spread from one person to another either directly or indirectly. The growing incidence of these diseases is largely attributed to the rise in global travel, which enables the rapid transmission of pathogens across borders. Neutralizing antibodies play a crucial role in treating infectious diseases by specifically targeting and blocking pathogens, thereby preventing the progression of illness. They contribute to improved patient outcomes by offering precise and timely immune protection. For example, in February 2024, the UK Health Security Agency reported that tuberculosis cases in England increased to 4,850 in 2023, up by 10.7% from 4,380 cases in 2022. This highlights how the rising prevalence of infectious diseases is bolstering the neutralizing antibody market.

Leading companies in the neutralizing antibody market are prioritizing the development of advanced therapies, including targeted treatments, to more effectively combat infectious diseases by directly neutralizing viruses and preventing their entry into human cells. Targeted therapies are designed to act on specific molecular markers or pathways that are essential for the growth and survival of disease-causing cells, such as those involved in cancers or viral infections. For instance, in February 2022, Eli Lilly and Company, a U.S.-based pharmaceutical firm, received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for Bebtelovimab, a neutralizing monoclonal antibody therapy aimed at treating COVID-19. Bebtelovimab is intended for use in patients with mild to moderate COVID-19 who are at high risk of progressing to severe disease, including hospitalization or death. This approval supports timely treatment efforts amid the emergence of new viral variants, thereby aiding in the reduction of disease severity and enhancement of patient outcomes.

In July 2022, Brii Biosciences Limited, a biotechnology firm based in China, collaborated with China Resources Pharmaceutical Commercial Group Co., Ltd. through its joint venture, TSB Therapeutics (Beijing) Co. Ltd., to support the commercialization of amubarvimab/romlusevimab in China. This partnership is focused on expanding access to the treatment for patients with mild to moderate COVID-19 who are at risk of developing severe illness, and accelerating its availability across the country. China Resources Pharmaceutical Commercial Group Co., Ltd. is engaged in the distribution of neutralizing antibody products within China.

Major players in the neutralizing antibody market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AstraZeneca PLC, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., GeNext Genomics, Celltrion Healthcare Co. Ltd, BeiGene Ltd, AbCellera Biologics Inc., BMC Pharmacology and Toxicology, Anthos Therapeutics, Immunome Inc., Sorrento Therapeutics Inc., Tonix Pharmaceuticals, Abwiz Bio, and AXIM Biotechnologies.

North America was the largest region in the neutralizing antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neutralizing antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neutralizing antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A neutralizing antibody is a specific type of antibody that attaches directly to a virus or pathogen, effectively blocking its ability to infect host cells. Its main function is to stop infection by neutralizing the pathogen’s harmful effects, thereby halting disease progression.

Neutralizing antibodies primarily come in two forms: monoclonal antibodies and polyclonal antibodies. Monoclonal antibodies are lab-engineered molecules tailored to bind to a specific antigen, such as a virus or cancer cell. These antibodies are used to target a range of viruses, including SARS-CoV-2 (COVID-19), HIV, influenza, Ebola, Zika, and hepatitis C, among others. Distribution channels include direct sales to end-users, distributors, online retailers, and other methods. Applications span across therapeutics, diagnostics, and research and development, catering to end-users such as hospitals and clinics, research institutions, diagnostic laboratories, pharmaceutical companies, and others.

The neutralizing antibody market research report is one of a series of new reports that provides neutralizing antibody market statistics, including neutralizing antibody industry global market size, regional shares, competitors with a neutralizing antibody market share, detailed neutralizing antibody market segments, market trends and opportunities, and any further data you may need to thrive in the neutralizing antibody industry. This neutralizing antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neutralizing antibody market consists of sales of antibody kits, reagents, and related diagnostic and therapeutic products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in usd, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Neutralizing Antibody Market Characteristics3. Neutralizing Antibody Market Trends And Strategies4. Neutralizing Antibody Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Neutralizing Antibody Growth Analysis And Strategic Analysis Framework
5.1. Global Neutralizing Antibody PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Neutralizing Antibody Market Growth Rate Analysis
5.4. Global Neutralizing Antibody Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Neutralizing Antibody Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Neutralizing Antibody Total Addressable Market (TAM)
6. Neutralizing Antibody Market Segmentation
6.1. Global Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Monoclonal Antibodies
  • Polyclonal Antibodies
6.2. Global Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • SARS-CoV-2 (COVID-19)
  • Human Immunodeficiency Viruses (HIV)
  • Influenza
  • Ebola
  • Zika
  • Hepatitis C
  • Other Target Viruses
6.3. Global Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Direct Sales To End-Users
  • Distributors
  • Online Retail
  • Other Distribution Channels
6.4. Global Neutralizing Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Therapeutics
  • Diagnostics
  • Research And Development
6.5. Global Neutralizing Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals And Clinics
  • Research Institutes
  • Diagnostic Laboratories
  • Pharmaceutical Companies
  • Other End Users
6.6. Global Neutralizing Antibody Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Fully Human Monoclonal Antibodies
  • Humanized Monoclonal Antibodies
  • Chimeric Monoclonal Antibodies
  • Murine Monoclonal Antibodies
6.7. Global Neutralizing Antibody Market, Sub-Segmentation Of Polyclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Animal-Derived Polyclonal Antibodies
  • Recombinant Polyclonal Antibodies
  • Human Polyclonal Antibody Preparations
7. Neutralizing Antibody Market Regional And Country Analysis
7.1. Global Neutralizing Antibody Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Neutralizing Antibody Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Neutralizing Antibody Market
8.1. Asia-Pacific Neutralizing Antibody Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Neutralizing Antibody Market
9.1. China Neutralizing Antibody Market Overview
9.2. China Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Neutralizing Antibody Market
10.1. India Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Neutralizing Antibody Market
11.1. Japan Neutralizing Antibody Market Overview
11.2. Japan Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Neutralizing Antibody Market
12.1. Australia Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Neutralizing Antibody Market
13.1. Indonesia Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Neutralizing Antibody Market
14.1. South Korea Neutralizing Antibody Market Overview
14.2. South Korea Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Neutralizing Antibody Market
15.1. Western Europe Neutralizing Antibody Market Overview
15.2. Western Europe Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Neutralizing Antibody Market
16.1. UK Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Neutralizing Antibody Market
17.1. Germany Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Neutralizing Antibody Market
18.1. France Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Neutralizing Antibody Market
19.1. Italy Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Neutralizing Antibody Market
20.1. Spain Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Neutralizing Antibody Market
21.1. Eastern Europe Neutralizing Antibody Market Overview
21.2. Eastern Europe Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Neutralizing Antibody Market
22.1. Russia Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Neutralizing Antibody Market
23.1. North America Neutralizing Antibody Market Overview
23.2. North America Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Neutralizing Antibody Market
24.1. USA Neutralizing Antibody Market Overview
24.2. USA Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Neutralizing Antibody Market
25.1. Canada Neutralizing Antibody Market Overview
25.2. Canada Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Neutralizing Antibody Market
26.1. South America Neutralizing Antibody Market Overview
26.2. South America Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Neutralizing Antibody Market
27.1. Brazil Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Neutralizing Antibody Market
28.1. Middle East Neutralizing Antibody Market Overview
28.2. Middle East Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Neutralizing Antibody Market
29.1. Africa Neutralizing Antibody Market Overview
29.2. Africa Neutralizing Antibody Market, Segmentation By Antibody Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Neutralizing Antibody Market, Segmentation By Target Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Neutralizing Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Neutralizing Antibody Market Competitive Landscape And Company Profiles
30.1. Neutralizing Antibody Market Competitive Landscape
30.2. Neutralizing Antibody Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
31. Neutralizing Antibody Market Other Major And Innovative Companies
31.1. Sanofi SA
31.2. GlaxoSmithKline plc
31.3. Eli Lilly and Company
31.4. Regeneron Pharmaceuticals Inc.
31.5. GeNext Genomics
31.6. Celltrion Healthcare Co. Ltd
31.7. BeiGene Ltd
31.8. AbCellera Biologics Inc.
31.9. BMC Pharmacology and Toxicology
31.10. Anthos Therapeutics
31.11. Immunome Inc.
31.12. Sorrento Therapeutics Inc.
31.13. Tonix Pharmaceuticals
31.14. Abwiz Bio
31.15. AXIM Biotechnologies
32. Global Neutralizing Antibody Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Neutralizing Antibody Market34. Recent Developments In The Neutralizing Antibody Market
35. Neutralizing Antibody Market High Potential Countries, Segments and Strategies
35.1 Neutralizing Antibody Market In 2029 - Countries Offering Most New Opportunities
35.2 Neutralizing Antibody Market In 2029 - Segments Offering Most New Opportunities
35.3 Neutralizing Antibody Market In 2029 - Growth Strategies
35.3.1 Market Trend Based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. About the Analyst
36.6. Copyright And Disclaimer

Executive Summary

Neutralizing Antibody Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neutralizing antibody market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase:

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Description

Where is the largest and fastest growing market for neutralizing antibody ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neutralizing antibody market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Antibody Type: Monoclonal Antibodies; Polyclonal Antibodies
2) By Target Virus: SARS-CoV-2 (COVID-19); Human Immunodeficiency Viruses (HIV); Influenza; Ebola; Zika; Hepatitis C; Other Target Viruses
3) By Distribution Channel: Direct Sales To End-Users; Distributors; Online Retail; Other Distribution Channels
4) By Application: Therapeutics; Diagnostics; Research And Development
5) By End User: Hospitals And Clinics; Research Institutes; Diagnostic Laboratories; Pharmaceutical Companies; Other End Users

Subsegments:

1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies; Humanized Monoclonal Antibodies; Chimeric Monoclonal Antibodies; Murine Monoclonal Antibodies
2) By Polyclonal Antibodies: Animal-Derived Polyclonal Antibodies; Recombinant Polyclonal Antibodies; Human Polyclonal Antibody Preparations

Key Companies Profiled: Pfizer Inc.; Johnson & Johnson; Roche Holding AG; Merck & Co. Inc.; AstraZeneca PLC

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery Format: PDF, Word and Excel Data Dashboard.

Companies Mentioned

  • Pfizer Inc.
  • Johnson & Johnson
  • Roche Holding AG
  • Merck & Co. Inc.
  • AstraZeneca PLC
  • Sanofi SA
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • Regeneron Pharmaceuticals Inc.
  • GeNext Genomics
  • Celltrion Healthcare Co. Ltd
  • BeiGene Ltd
  • AbCellera Biologics Inc.
  • BMC Pharmacology and Toxicology
  • Anthos Therapeutics
  • Immunome Inc.
  • Sorrento Therapeutics Inc.
  • Tonix Pharmaceuticals
  • Abwiz Bio
  • AXIM Biotechnologies.